Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax, Inc. (Nasdaq: NVAX) announced that John C. Jacobs will succeed Stanley C. Erck as President and CEO effective January 23, 2023. Erck will assist in the leadership transition for 15 months. Jacobs brings over 25 years of industry experience, having led Harmony Biosciences through its IPO and FDA product approval. Under Erck's leadership since 2011, Novavax launched its COVID-19 vaccine in over 40 countries. The company is positioned to continue its strategic development with multiple vaccine candidates in progress.
Novavax, Inc. (Nasdaq: NVAX) has initiated a Phase 2 trial for its COVID-19-Influenza Combination (CIC) vaccine and a stand-alone influenza vaccine. This dose-confirming trial will assess safety and immunogenicity in adults aged 50-80 and aims to enroll around 2,300 participants across Australia and New Zealand. Initial results are expected mid-2023, which will guide the Phase 3 trials. The company draws optimism from earlier positive results from the Phase 1/2 trial, focusing on providing better protection against influenza and COVID-19, especially for older adults.
On December 20, 2022, Novavax (Nasdaq: NVAX) completed a $150 million offering of 5.00% Senior Convertible Notes due 2027, with an additional $25.25 million purchased by initial buyers. Also, a public offering of 7,475,000 shares of common stock raised $74.75 million. The combined gross proceeds from both offerings amount to $250 million. The Notes are convertible at $12.50 per share, representing a 25% conversion premium. Novavax estimates net proceeds of approximately $166.3 million from the Notes and $69.8 million from the stock offering, earmarked for corporate purposes.
Novavax, Inc. (Nasdaq: NVAX) announced a $150 million offering of 5.00% convertible senior notes due 2027, with an option for initial purchasers to buy an additional $25.25 million. The notes will accrue interest semi-annually and are redeemable post December 22, 2025. Concurrently, a public offering of 6,500,000 shares of common stock at $10.00 per share, totaling $65 million, has been priced. Proceeds will support global launches, operational costs, and R&D. Offerings are expected to close on December 20, 2022.
Novavax, Inc. (Nasdaq: NVAX) has announced the pricing of a public offering of 6,500,000 shares of common stock at $10.00 per share, raising approximately $65 million. The underwriters have a 30-day option to buy an additional 975,000 shares. Concurrently, Novavax priced $150 million in convertible senior notes due in 2027. The net proceeds will be used for general corporate purposes, including the global launch of Nuvaxovid and repaying outstanding senior notes. Both offerings are expected to close on December 20, 2022, subject to customary conditions.
Novavax, Inc. (Nasdaq: NVAX) announced a proposed underwritten public offering of up to $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. Concurrently, the company plans to offer $125 million in convertible senior notes due 2027, also with a $18.75 million additional option. The proceeds will be used for general corporate purposes, including the global launch of Nuvaxovid, working capital, R&D, and debt repayment.
Novavax, Inc. (Nasdaq: NVAX) announced a proposed offering of $125 million in convertible senior notes due 2027. These notes will be sold to qualified institutional buyers under Rule 144A. The company may also offer up to $125 million in common stock, with an additional $18.75 million option for both offerings. Proceeds will support general corporate purposes, including the launch of Nuvaxovid and repay existing convertible notes. The offering is not contingent on the other, and the financial terms will be set at pricing.
On December 7, 2022, Novavax, Inc. (Nasdaq: NVAX) announced that Health Canada has approved the Nuvaxovid COVID-19 Vaccine for use as a primary series for adolescents aged 12 to 17. This approval is based on data from the Phase 3 PREVENT-19 trial, demonstrating a clinical protective efficacy of 79.5%, particularly against the Delta variant. Nuvaxovid is already authorized in over 10 markets globally, including the U.S. and European Union. The vaccine will be manufactured in Montreal, with engineering runs completed and production of qualification batches expected to start in early 2023.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company focused on developing vaccines for infectious diseases, announced its participation in the BofA Securities 2022 Virtual Biotech SMID Cap Conference on December 7, 2022. The fireside chat will feature discussions on its recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, from 9:10 – 9:35 a.m. EST. Novavax executives, including Chief Medical Officer Filip Dubovsky, will participate. A recording will be available on the company’s website for 90 days post-conference.
Novavax, Inc. (Nasdaq: NVAX) announced an updated Emergency Use Listing (EUL) from the WHO for its Nuvaxovid™ COVID-19 vaccine. This listing allows the vaccine to be used as a primary series for adolescents aged 12-17 and as a booster for adults 18 and older. Clinical data demonstrated Nuvaxovid's efficacy of 80% in adolescents during the Delta variant surge, with a low incidence of adverse reactions. The vaccine is authorized in over 10 markets, including the U.S. and EU, and the company continues trials for additional indications.